Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Deals Of The Week: Sandoz/Fougera, Abbott/Action Pharma/Zealand, AstraZeneca/Axerion

Executive Summary

New company Tolero helps MannKind de-risk a preclinical BTK inhibitor program in a “double-jointed” deal in which the “bio-bucks” eventually could flow in either direction.

Advertisement

Related Content

Abbott Adds To Renal Pipeline In Deal With Action Pharma
AstraZeneca Goes Virtual In Neuroscience R&D As Part Of Workforce Reduction
Takeda Boosts European, Emerging Markets Footprint With $13.6B Nycomed Buy
MannKind Shares Game Plan For Tackling Afrezza's Complete Response
Abbott Pays $450MM Up-Front For Rights To Reata's CKD Drug
With $35 Million B Round, Trevena to Push GPCR-Targeted Program into Phase II for Acute Heart Failure
Axerion Therapeutics Inc.
Abbott Joins Race To Develop Nerve Growth Factor Antibody With PanGenetics Deal
Hologic Gains HPV Test Technology In $580 Million Third Wave Purchase
Cytyc Together with Hologic: There's a Certain Logic

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

PS054425

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel